Core Insights - Keros Therapeutics, Inc. is advancing its lead asset, rinvatercept, targeting neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD), with a focus on improving muscle and bone outcomes through modulation of the transforming growth factor-beta pathway [1][4] Development Updates - A recent phase I update, orphan drug designation, and plans for a phase II trial starting in Q2 2026 have positioned rinvatercept as a central narrative for the company [2][10] - The FDA granted orphan drug designation to rinvatercept for DMD in August 2025, which is expected to streamline the development strategy and regulatory path [7][8] Mechanism of Action - Rinvatercept (KER-065) is designed to selectively inhibit transforming growth factor-beta ligands, including myostatin and activin A, which are negative regulators of muscle and bone mass [3] - By blocking these pathways, the company aims to promote muscle regeneration, increase muscle size and strength, reduce fat accumulation, and enhance bone strength [4] Competitive Landscape - Keros highlights that glucocorticoids are the current standard of care for DMD but have significant side effects, creating an opportunity for rinvatercept to offer a differentiated therapeutic approach [5][6] - The competitive landscape includes Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc., which have established therapies for DMD, making efficient advancement of rinvatercept critical for investor confidence [13] Clinical Data and Future Plans - Phase I data indicated that rinvatercept was well tolerated, showing benefits in muscle mass, fat reduction, and bone density, which supports its intended mechanism [9][11] - The next key milestone is the initiation of a phase II trial for DMD in Q2 2026, which will be crucial for maintaining momentum and investor interest [12][15] Strategic Focus - Keros has concentrated its efforts on rinvatercept, making execution of this single program a significant driver of investor sentiment, with any delays potentially impacting confidence [14]

Core Insights - Keros Therapeutics (KROS) experienced a significant revenue increase in 2025, but the sustainability of this growth is uncertain due to reliance on one-time licensing revenue rather than consistent product sales [1][4][10] Revenue Performance - Keros reported total revenue of $244.1 million in 2025, a substantial rise from $3.6 million in 2024, primarily driven by licensing and transition services from its partnership with Takeda [2][10] - License revenue accounted for $205.4 million, including a $200 million upfront payment and a $10 million development milestone, while service revenue totaled $38.7 million [3][10] Earnings Quality - The revenue structure is heavily reliant on one-time license recognition, which may lead to volatility in future earnings if milestone timing is inconsistent [5][6] - In Q4 2025, Keros generated only $0.4 million in revenue, all from service-related activities, indicating a lack of product sales and highlighting the dependency on partner-driven revenue [6][10] Cost Structure - Following the Takeda transition, Keros has a leaner cost structure, with R&D expenses decreasing by 61% year-over-year to $17.9 million, allowing for reduced cash burn [7][8] - This shift enables the company to focus on its lead program, rinvatercept, while benefiting from Takeda's support on elritercept [8] Financial Position - Keros ended 2025 with $287.4 million in cash, which is projected to fund operations into the first half of 2028 under current assumptions [9][11] - The cash runway reduces immediate financing concerns and provides time for advancing rinvatercept through clinical and regulatory phases [11] Capital Return Strategy - Keros undertook significant capital return actions in 2025, including a tender offer of approximately $194.4 million and share repurchases totaling about $180.6 million, resulting in a 49% decrease in year-end cash balance [13] - The reduction in shares outstanding to 19.5 million may enhance per-share metrics but also diminishes the cash cushion [14] Competitive Landscape - The competitive environment is challenging, with established players like Sarepta Therapeutics and PTC Therapeutics in the Duchenne muscular dystrophy space, emphasizing the need for Keros to demonstrate consistent execution and revenue generation [17]

Core Insights - Keros Therapeutics (KROS) is entering 2026 with a clearer focus on operational execution and a defined catalyst stack, primarily driven by rinvatercept [1][2] - The company has shifted costs related to elritercept to Takeda, allowing for a leaner R&D base and a longer operational runway [2] Rinvatercept as a Central Value Driver - Rinvatercept is positioned as the key value driver in Keros' pipeline, designed to inhibit negative regulators of muscle and bone mass [3] - The drug aims to promote muscle regeneration, increase muscle size and strength, reduce body fat, and improve bone strength [4] Upcoming Milestones - A pivotal milestone is the expected start of a Phase II study of rinvatercept in Duchenne muscular dystrophy (DMD) in Q2 2026, which is crucial for Keros as it is their lead program [5][10] - The Phase II trial is significant as it aims to test the drug's clinical benefits against the current standard of care, glucocorticoids, which have long-term side effects [6] Regulatory Engagement for ALS - Keros plans to engage with regulatory authorities in the second half of 2026 to discuss a Phase II study for rinvatercept in amyotrophic lateral sclerosis (ALS) [7][8] Data Support and Clinical Profile - A March 2023 update indicated that rinvatercept was well tolerated with no serious adverse events, supporting its mechanism and potential benefits [9][11] - The update also highlighted increases in muscle mass, reduced fat, and higher bone density, reinforcing the drug's target engagement [11] Competitive Landscape in DMD - The DMD therapeutic area is competitive, with established players like Sarepta Therapeutics and PTC Therapeutics, necessitating Keros to demonstrate a clear clinical profile [12][14] - Sarepta has multiple therapies and recent approvals, while PTC markets Emflaza, underscoring the need for differentiation [13][14] Financial Considerations - Keros has not recorded product sales and relies on licensing and transition-service revenue, leading to potential volatility in financials until a commercial engine is defined [15] - The company ended 2025 with $287.4 million in cash, expected to fund operations into the first half of 2028, contingent on current assumptions [16]

Keros Therapeutics Conference Call Summary Company Overview - **Company**: Keros Therapeutics (NasdaqGM: KROS) - **Event**: 2026 Conference at the Leerink Partners Global Healthcare Conference - **Speaker**: CEO Jas Sira Key Highlights from 2025 - **Takeda Partnership**: The partnership with Takeda was established at the end of 2024, transitioning the elritercept program to Takeda, which is now responsible for its development. Keros will continue to advise on the program [4] - **Clinical Trials**: Takeda is advancing elritercept into Phase III trials for myelofibrosis, with decisions expected later in the year [4] - **Cibotercept Program**: The program was deprioritized due to safety signals, leading to a halt in dosing [5] - **Rinvatercept Development**: Keros plans to advance rinvatercept into neuromuscular indications, specifically targeting Duchenne Muscular Dystrophy (DMD) and Amyotrophic Lateral Sclerosis (ALS) [5][6] Pipeline and Platform - **TGF-beta Superfamily Focus**: Keros continues to focus on the TGF-beta pathway, utilizing ligand traps based on activin receptors for various indications [9][10] - **Rinvatercept Mechanism**: Rinvatercept inhibits activin A and myostatin, promoting muscle regeneration by counteracting negative regulators of skeletal muscle [12][13] Clinical Data and Efficacy - **Duchenne Muscular Dystrophy (DMD)**: - Rinvatercept showed promising results in healthy volunteers, including increases in lean mass and improvements in bone mineral density [19] - The drug aims to reduce fat mass, particularly unhealthy abdominal fat, which is significant for DMD patients who may develop metabolic syndrome [19] - **Phase 2 Study Design**: The study will include late ambulatory and non-ambulatory cohorts to evaluate safety and efficacy signals [22][23] ALS Development - **Mechanism in ALS**: The focus is on preserving muscle function despite the loss of neuromuscular junctions, with preclinical data showing treated animals maintaining better weight and grip strength compared to untreated ones [38][39] - **Regulatory Engagement**: Keros plans to engage with the FDA regarding trial design and patient population targeting slow-progressing ALS cases [43] Elritercept and Takeda Partnership - **Phase 2 Results**: Elritercept demonstrated a 50% response rate in treating anemia in MDS patients, differentiating itself from luspatercept by binding to activin A [52] - **Revenue Potential**: The partnership includes a $200 million upfront payment and up to $1.1 billion in milestone payments, with royalties starting in low double digits [60][61] Future Outlook - **Pipeline Expansion**: Keros anticipates advancing additional assets into the clinic by the first half of 2028, with ongoing updates expected throughout the year [62] Conclusion - Keros Therapeutics is positioned for significant advancements in its clinical programs, particularly in DMD and ALS, while leveraging its partnership with Takeda to enhance its market presence in anemia treatments. The focus on innovative mechanisms and robust clinical data supports a positive outlook for the company's future endeavors.

Core Insights - Keros Therapeutics, Inc. announced additional data from its Phase 1 clinical trial of rinvatercept (KER-065), highlighting its potential in treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [1][2] Clinical Development - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving healthy adult male volunteers, focusing on safety, tolerability, and pharmacokinetics of rinvatercept [2] - Initial topline data from the trial was reported in March 2025, indicating that rinvatercept was well-tolerated across all evaluated dose levels, with no serious adverse events reported [3] Mechanism of Action - Rinvatercept demonstrated effects consistent with activin and myostatin inhibition, leading to increased muscle mass, decreased fat mass, and improved bone mineral density [3] - Proteomic analysis indicated that rinvatercept mitigates fibrosis and inflammation, aligning with preclinical observations of its anti-fibrotic and anti-inflammatory properties [4] Product Overview - Rinvatercept is a novel ligand trap designed to inhibit the biological effects of myostatin and activin A, which negatively regulate muscle and bone mass, aiming to enhance muscle regeneration and overall skeletal health [5][8] - The company is also developing elritercept for treating cytopenias in patients with myelodysplastic syndrome and myelofibrosis [8]

Core Viewpoint - Keros Therapeutics has entered into a collaboration with Massachusetts General Hospital to design a Phase 2 clinical trial for rinvatercept in patients with amyotrophic lateral sclerosis (ALS) as part of the Healey ALS MyMatch program [1][2][3] Group 1: Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins [1][7] - The company's lead product candidate, rinvatercept, is being developed for the treatment of both Duchenne muscular dystrophy and ALS [1][8] Group 2: Clinical Trial and Collaboration - The collaboration with the Healey & AMG Center aims to accelerate the development of new therapies for ALS through biomarker-driven personalized trial approaches [2][4] - The ALS MyMatch program integrates genetic and biofluid markers to match ALS patients with experimental therapies based on their disease markers [2][4] - Rinvatercept is believed to have the potential to preserve muscle strength and improve quality of life for ALS patients, according to Keros' CEO [3][6] Group 3: Research and Development - Rinvatercept functions as a ligand trap to inhibit the biological effects of myostatin and activin A, which negatively regulate muscle and bone mass [6] - The Healey ALS MyMatch program is a multi-site initiative involving several high-enrolling ALS research centers, aimed at enhancing the understanding of biological effects of experimental products [4][5]

Core Insights - Keros Therapeutics, Inc. announced additional data from its Phase 1 clinical trial of rinvatercept (KER-065), highlighting its potential in treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [1][2] Clinical Development - The Phase 1 trial was a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics of rinvatercept in healthy adult male volunteers [3] - Initial topline data from the trial was reported in March 2025, indicating that rinvatercept was well-tolerated at all evaluated dose levels, with no serious adverse events reported [4] Mechanism of Action - Rinvatercept demonstrated effects consistent with activin and myostatin inhibition, leading to increased muscle mass, decreased fat mass, and improved bone mineral density [4] - Proteomic data indicated that rinvatercept may mitigate fibrosis and inflammation, aligning with preclinical observations of its anti-fibrotic and anti-inflammatory effects [5] Future Trials - Keros plans to advance rinvatercept into two Phase 2 clinical trials targeting DMD and ALS, reinforcing its commitment to developing this therapeutic [2] Product Overview - Rinvatercept is designed as a ligand trap to inhibit the negative regulators of muscle and bone mass, aiming to improve muscle regeneration, increase muscle size and strength, and enhance bone health [6] - The company is also developing elritercept for treating cytopenias in patients with myelodysplastic syndrome and myelofibrosis [8]

Core Insights - Keros Therapeutics (KROS) is focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-β protein family [1] Group 1: Product Development - Rinvatercept, KROS' lead candidate, selectively binds and inhibits TGF-β ligands, potentially promoting muscle regeneration, increasing muscle size and strength, reducing body fat and fibrosis, and enhancing bone strength [2] - KROS is advancing rinvatercept for the treatment of Duchenne muscular dystrophy (DMD) and plans to begin a phase II trial in DMD patients in Q1 2026 [3][4] - The FDA granted orphan drug designation for KER-065 for DMD treatment in August 2025 [3][10] - KROS is also developing rinvatercept for amyotrophic lateral sclerosis (ALS) and plans to engage with regulatory authorities in H2 2026 for a phase II study [4] Group 2: Competitive Landscape - DMD is a competitive therapeutic area, with current treatments primarily involving corticosteroids [6] - Sarepta Therapeutics (SRPT) is a significant competitor with a strong DMD franchise, including gene therapies like Elevidys, which received accelerated approval from the FDA [7][8] - PTC Therapeutics, Inc. (PTCT) markets Emflaza for DMD and has faced challenges with its other drug, Translarna, in the European market [9][12] Group 3: Financial Performance - KROS shares have gained 2.9% over the past year, compared to the industry's rise of 15.9% [13] - The company's shares trade at 0.51x tangible book value, significantly lower than the industry average of 3.76x [15] - The Zacks Consensus Estimate for 2026 loss per share is $3.36, unchanged over the past week, with a projection of $4.34 for 2027 [16][18]

Financial Performance - The company reported a net income of $87.0 million for the year ended December 31, 2025, compared to a net loss of $187.4 million for the year ended December 31, 2024[570]. - Total revenue for the year ended December 31, 2025, was $244.1 million, a significant increase from $3.6 million in 2024[598]. - License revenue from the Takeda Agreement was $205.4 million for 2025, compared to $3.0 million in 2024[599]. - The company recognized $24.9 million in dividend income for 2025, compared to $23.5 million in 2024[603]. - The income tax provision for 2025 was $4.9 million, up from $0.3 million in 2024, due to taxable income from the Takeda Agreement[604]. - The company reported a net income of $87.0 million for the year ended December 31, 2025, compared to a net loss of $187.4 million for the year ended December 31, 2024[606]. - As of December 31, 2025, the company had an accumulated deficit of $481.8 million, down from $568.8 million as of December 31, 2024[606]. Cash and Liquidity - As of December 31, 2025, the company had cash and cash equivalents of $287.4 million, expected to fund operations into the first half of 2028[574]. - Cash and cash equivalents as of December 31, 2025, were $287.4 million, expected to fund liquidity requirements into the first half of 2028[611]. - Net cash provided by operating activities was $107.5 million for the year ended December 31, 2025, driven by a net income and non-cash charges[614]. - Net cash used in financing activities was $378.5 million for the year ended December 31, 2025, primarily due to share repurchases totaling $375.0 million[618]. - The company plans to distribute 25% of any net cash proceeds from the Takeda Agreement to stockholders by December 31, 2028[622]. Share Transactions - The company has sold a total of 4,290,096 shares under the ATM Sales Agreement for aggregate net proceeds of approximately $228.6 million[565]. - In January 2024, the company closed a public offering, issuing 4,025,000 shares at a price of $40.00 per share, resulting in net proceeds of approximately $151.1 million[566]. - The company accepted for purchase 10,950,165 shares at a price of $17.75 per share during the Tender Offer, totaling approximately $194.4 million[569]. - The company completed a Tender Offer in November 2025, purchasing 10,950,165 shares at a price of $17.75 per share, totaling approximately $194.4 million[610]. Research and Development - The company has incurred recurring operating losses each fiscal year since its inception in 2015, with an accumulated deficit of $481.8 million as of December 31, 2025[570]. - The company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization[563]. - The company expects to continue to incur operating losses and negative cash flows as it advances its product candidates through clinical development[572]. - Research and development expenses decreased to $129.6 million in 2025 from $173.6 million in 2024, a reduction of $44.0 million[600]. - Research and development incentive income from the Australian government was $1.2 million in 2024, but no income was recognized in 2025[603]. - The company is entitled to receive up to $1.1 billion in additional milestone payments under the Takeda Agreement, including $80.0 million for development milestones and $280.0 million for commercial milestones[585]. Agreements and Contracts - The company entered into a licensing agreement with Takeda Pharmaceuticals for the development and commercialization of elritercept, effective January 16, 2025[562]. - The company received a $200.0 million upfront payment from Takeda in February 2025, along with a $10.0 million milestone payment in August 2025[585]. - The company is entitled to receive up to $23.5 million in development milestone payments and $144.0 million upon achieving specified net sales thresholds under the Hansoh Agreement[580]. Operating Expenses - General and administrative expenses increased to $46.8 million in 2025 from $40.8 million in 2024, an increase of $6.1 million[602]. Accounting Policies - The company recognizes revenue based on the transfer of control for goods or services, with distinct licenses recognized when transferred to the customer[630]. - Payments from customers are recorded as deferred revenue until obligations are satisfied, with accounts receivable recognized when the right to consideration is unconditional[631]. - The company estimates accrued research and development expenses based on known facts and circumstances, with adjustments made if actual performance varies from estimates[632]. - Stock-based compensation is recognized at fair value, with costs allocated over the vesting period or based on performance conditions using the Black-Scholes option-pricing model[633]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[636].

Financial Performance - Keros reported a net loss of $23.5 million for Q4 2025, a significant improvement from a net loss of $46.0 million in Q4 2024, and achieved a net income of $87.0 million for the full year 2025 compared to a net loss of $187.4 million in 2024[3] - Total revenue for 2025 was $244.1 million, with license revenue contributing $205.4 million, compared to $3.0 million in 2024[14] - Keros' accumulated deficit improved to $481.8 million as of December 31, 2025, from $568.8 million in 2024[16] Expenses - Research and development expenses decreased to $17.9 million in Q4 2025 from $45.6 million in Q4 2024, and for the full year, expenses were $129.6 million compared to $173.6 million in 2024[4] - General and administrative expenses increased to $11.7 million in Q4 2025 from $10.7 million in Q4 2024, and for the full year, they rose to $46.8 million from $40.8 million in 2024[5] Cash and Assets - Keros' cash and cash equivalents as of December 31, 2025, were $287.4 million, down from $559.9 million at the end of 2024, primarily due to share repurchases and cash tender offers[7] - Keros' total assets decreased to $338.0 million as of December 31, 2025, from $615.9 million in 2024, reflecting a reduction in cash and cash equivalents[16] - The company expects its cash reserves will fund operations into the first half of 2028 based on current operating assumptions[7] Future Plans - The company plans to initiate a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD) in Q2 2026 and engage regulators for a Phase 2 trial in amyotrophic lateral sclerosis (ALS) in H2 2026[5] Stock Information - The weighted-average common stock outstanding was 27,198,653 for Q4 2025, compared to 40,337,720 for Q4 2024[14]